Le traitement monodose de la cystite non compliquée chez la femme à propos d'un essai fosfomycine trométamol (Monuril®) versus péfloxacine

Richaud, C

doi:10.1016/s0399-077x(05)80760-7

Cited by 6 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…За час застосування в клінічній практиці проведено близько 60 контрольованих клінічних досліджень застосування пероральної форми фосфоміцину при гострому циститі, а також опубліковано результати метааналізів щодо цієї теми [3,7,13,16,17,19,21,22,. Вживання разової дози 3 г препарату порівнювали з хінолонами і фторхінолонами -норфлоксацином [27,32,33,36,37,42], ципрофлоксацином [41,52], офлоксацином [29], пефлоксацином [53], нітрофуранами [16,25,38,44,54], цефалоспоринами [39,55], амінопеніцилінами [28,48] і аміноглікозидами [26], а також триметопримом [31,43] та поєднанням сульфаметоксазолу/триметоприму (TMP/SMX) [29,30].…”

Section: ефективність фосфоміцину при інфекціях сечових шляхівunclassified

New Horizons for the Role of Fosfomycin in the Era of Multi-drug Resistant Urinary Tract Infections

Shostak,

Kostyev,

Krasylyuk

et al. 2023

View full text Add to dashboard Cite

The genital-urinary system is a complex of organs which are anatomically and physiologically interconnected. Therefore, infectious diseases of the urinary tract can affect the urethra, bladder and urethra, kidneys and prostate gland. Urinary tract infections (UTIs) are characterized by the presence of bacteria, viruses, fungi or parasites in the urinary tract, which cause inflammation and form the clinical picture of the disease. Despite the fact that fosfomycin is an antibiotic with a long history, it has unique properties that make it an effective antibiotic therapy for UTIs with consistently low resistance patterns of uropathogens. It is an antibacterial drug with a chemical structure that is not similar to other known antibiotics and is considered a strong alternative in the treatment of infections caused by multi-resistant pathogens, has a wide spectrum of action against gram-positive and gram-negative microorganisms, including many antibiotic-resistant microorganisms. Current data indicate the ability to penetrate biofilms of uropathogens, synergistically enhance the transport of other antibiotics inside bacterial cells, as well as a significant reduction in the virulence of pathogens when fosfomycin resistance is acquired. Fosfomycin has such advantages as a high concentration in the urinary tract, a minimal effect on the gastrointestinal flora and a practical lack of tendency to form resistance. Today, the safety and effectiveness of the drug has been proven as a means of antibiotic prophylaxis after operations on the lower urinary tract, transrectal biopsy of the prostate gland and frequently recurrent UTIs, in the treatment of asymptomatic bacteriuria and UTIs during pregnancy, in the treatment of chronic bacterial prostatitis, as well as a part of antimicrobial measures in multiresistant bacterial strains.

show abstract

Section: ефективність фосфоміцину при інфекціях сечових шляхівunclassified

New Horizons for the Role of Fosfomycin in the Era of Multi-drug Resistant Urinary Tract Infections

Shostak,

Kostyev,

Krasylyuk

et al. 2023

View full text Add to dashboard Cite

show abstract

Fosfomycin Trometamol: A Review of Its Use as a Single-Dose Oral Treatment for Patients with Acute Lower Urinary Tract Infections and Pregnant Women with Asymptomatic Bacteriuria

Keating

2013

Drugs

View full text Add to dashboard Cite

Fosfomycin trometamol (fosfomycin tromethamine) [Monuril(®), Monurol(®), Monural(®)] is approved in numerous countries worldwide, mainly for the treatment of uncomplicated urinary tract infections (UTIs). Fosfomycin has good in vitro activity against common uropathogens, such as Escherichia coli (including extended-spectrum β-lactamase-producing E. coli), Proteus mirabilis, Klebsiella pneumoniae and Staphylococcus saprophyticus, and the susceptibility of uropathogens to fosfomycin has remained relatively stable over time. A single oral dose of fosfomycin trometamol 3 g (the approved dosage) achieves high concentrations in urine. Results of recent randomized trials indicate that single-dose fosfomycin trometamol had similar clinical and/or bacteriological efficacy to 3- to 7-day regimens of ciprofloxacin, norfloxacin, cotrimoxazole or nitrofurantoin in women with uncomplicated lower UTIs. In addition, single-dose fosfomycin trometamol had similar bacteriological efficacy to a 5-day course of cefuroxime axetil or a 7-day course of amoxicillin/clavulanic acid in pregnant women with asymptomatic bacteriuria, and similar clinical and/or bacteriological efficacy to a 5-day course of cefuroxime axetil or amoxicillin/clavulanic acid or a 3-day course of ceftibuten in pregnant women with a lower UTI. Single-dose fosfomycin trometamol was generally well tolerated, with gastrointestinal adverse events (e.g. diarrhoea, nausea) reported most commonly. In conclusion, single-dose fosfomycin trometamol is an important option for the first-line empirical treatment of uncomplicated lower UTIs.

show abstract

Le traitement monodose de la cystite par fosfomycine trométamol (Monuril®) : analyse de 15 essais comparatifs portant sur 2048 malades

Lecomte

Allaert²

1996

Médecine et Maladies Infectieuses

View full text Add to dashboard Cite

Le traitement monodose de la cystite non compliquée chez la femme à propos d'un essai fosfomycine trométamol (Monuril®) versus péfloxacine

Cited by 6 publications

References 15 publications

New Horizons for the Role of Fosfomycin in the Era of Multi-drug Resistant Urinary Tract Infections

New Horizons for the Role of Fosfomycin in the Era of Multi-drug Resistant Urinary Tract Infections

Fosfomycin Trometamol: A Review of Its Use as a Single-Dose Oral Treatment for Patients with Acute Lower Urinary Tract Infections and Pregnant Women with Asymptomatic Bacteriuria

Le traitement monodose de la cystite par fosfomycine trométamol (Monuril®) : analyse de 15 essais comparatifs portant sur 2048 malades

Contact Info

Product

Resources

About